Search

agbiopro
- Jun 20, 2019
- 0 min read

With $45M Nurix Deal, Gilead Enters Crowded Protein Degradation Field

Recent Posts

ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing

GentiBio Launches with $20 Million Seed Funding from Novartis and Others

Kymera Therapeutics Unveils IPO Pitch for Protein Degradation